Pillstats
Rx only · Injection, Solution · Subcutaneous

Adalimumab-Aqvh

Brands: Yusimry · Adalimumab

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US4 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCL04AB04
RxCUI (US)327361
US makers2 labelers
Packages4
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$173.69$347.39$521.08$694.78May 2025Oct 2025Oct 2025
$604.153
Latest avg · Oct 29, 2025
+0%
Since May 21, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

971932903862025 Q12025 Q22025 Q32025 Q42026 Q1
237
Rx · 2026 Q1
454
Units dispensed
-29%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Meitheal Pharmaceuticals Inc.unknown2SUPPLYING
Coherus BioSciences Incunknown2SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.